Q-omics provides the consensus-scored UBTFL6 profile across patient tissues and cancer cell-line models. UBTFL6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UBTFL6 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, UBTFL6 RNA expression shows 15,726 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where UBTFL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBTFL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBTFL6 survival associations across molecular data types. UBTFL6 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBTFL6 RNA expression–survival associations across cancer types. High UBTFL6 expression shows unfavorable associations in LGG, but favorable associations in KIRC, UCS, THCA, HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UBTFL6 RNA expression.
This table summarizes UBTFL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for UBTFL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBTFL6 shows lower tumor expression in UCEC and higher tumor expression in KIRC, LIHC, HNSC, THCA and COAD. The KIRC box plot shows higher UBTFL6 RNA expression in tumor versus normal tissue (log2 FC = +1.283, t-test p < 0.001).
This table shows molecular features associated with UBTFL6 in patient tissues and cancer cell lines. In patient samples, UBTFL6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
